Original Investigation
Perioperative Camrelizumab Plus Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
JAMA Oncology 10.1001/jamaoncol.2026.4642November 12, 2026 at 11:00 AM EST
In this phase 2 randomized clinical trial, perioperative camrelizumab plus chemotherapy significantly improved EFS with manageable toxic effects, supporting evaluation of intensified perioperative immune priming in resectable HNSCC.
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Need more information? Contact us.